Murine antithymocyte globulin T-cell depletion is mediated predominantly by macrophages, but the fas/fasl pathway selectively targets regulatory T cells

Transplantation

Volumn 92, Issue 5, 2011, Pages 523-528

  Neff, Kathleen S ^a   Richards, Susan M ^a   Williams, John M ^a   Garman, Richard D ^a   Ruzek, Melanie C ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Antithymocyte globulin; Fas; Macrophages; Murine; T cell depletion

Indexed keywords

COMPLEMENT COMPONENT C5; FAS ANTIGEN; FAS LIGAND; THYMOCYTE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; EFFECTOR CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MEMORY T LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD95; ANTILYMPHOCYTE SERUM; APOPTOSIS; COMPLEMENT C5; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MACROPHAGES; MICE; NEUTROPHILS; RABBITS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 80052398914     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822923f7     Document Type: Article

References (41)

1. Beiras-Fernandez A, Thein E, Hammer C. Induction of immunosuppression with polyclonal antithymocyte globulins: An overview. Exp Clin Transplant 2003; 2: 79.
2. Lowsky R, Sahaf B, Shizuru J, et al. Haploidentical non-myeloablative allogeneic hematopoietic cell transplantation (HCT) using total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) conditioning protects acute graft versus host disease (GVHD) [abstract]. Blood 2005; 106: 2904.
3. Cruzado J, Bestard O, Grinyo J. New immunosuppressive protocols with the advent of novel biological drugs. Transplantation 2009; 88: S20.
4. Bonnefoy-Berard N, Revillard J. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996; 15: 435.
5. Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460.
6. Brennan DC. Faith supported by reason: Mechanistic support for the use of polyclonal antibodies in transplantation. Transplantation 2003; 75: 657.
7. Lopez M, Clarkson M, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+CD25+Foxp3+regulatory T cells. J Am Soc Nephrol 2006; 17: 2844.
8. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387.
9. Pearl J, Parris J, Hale D, et al. Immunocompetent T-cells with a memorylike phenotype are the dominant cell type following antibodymediated T-cell depletion. Am J Transplant 2005; 5: 465.
10. Minamimura K, Gao W, Maki T. CD4+regulatory T cells are spared from depletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J Immunol 2006; 176: 4125.
11. Ruzek M, Neff K, Luong M, et al. In vivo characterization of rabbit anti-mouse thymocyte globulin: A surrogate for rabbit anti-human thymocyte globulin. Transplantation 2009; 88: 170.
12. Genestier L, Fournel S, Flacher M, et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91: 2360.
13. Dubey S, Nityanand S. Involvement of Fas and TNF pathways in the induction of apoptosis of T cells by antithymocyte globulin. Ann Hematol 2003; 82: 496.
14. Bonnefoy-Berard N, Fournel S, Genestier L, et al. In vitro functional properties of antithymocyte globulins: Clues for new therapeutic applications. Transplant Proc 1998; 30: 4015.
15. Zand M, Vo T, Pellegrin R, et al. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood 2006; 107: 2895.
16. Ayuk F, Atassi N, Schuch G, et al. Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia. Leuk Res 2008; 32: 1200.
17. Barth B, Carroll G. Immunosuppressive effects of antilymphocyte serum in complement-deficient mice: Evidence that immune cytolysis is not essential for ALS activity. J Immunol 1970; 104: 522.
18. Barth R, Singla O,WardP. Immunosuppressive effects of anti-lymphocyte serum in complement deficient mice. II. Evidence that activity is mediated by C3 independent antibodies. J Immunol 1974; 112: 858.
19. Genestier L, Bonnefoy-Berard N, Revillard JP. Apoptosis of activated peripheral T cells. Transplant Proc 1999; 31: 33S.
20. Ayuk F, Fang L, Fehxe B, et al. Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. Exp Hematol 2005; 33: 1531.
21. Zand M, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79: 1507.
22. Taams L, Smit J, Rustin M, et al. Human anergic/suppressive CD4(+)CD25(+) T cells: A highly differentiated and apoptosis-prone population. Eur J Immunol 2001; 31: 1122.
23. Banz A, Pontoux C, Papiernik M. Modulation of Fas-dependent apoptosis: A dynamic process controlling both the persistence and death of CD4 regulatory T cells and effector T cells. J Immunol 2002; 169: 450.
24. Fritzsching B, Oberle N, Eberhardt N, et al. In contrast to effector T cells, CD4+CD25+Foxp3+regulatory T cells are highly susceptible to CD95 ligand but not to TCR-mediated cell death. J Immunol 2005; 175: 32.
25. Mohamood A, Trujillo C, Zheng D, et al. Gld mutation of Fas ligand increases the frequency and up-regulates cell survival genes in CD25+CD4+TR cells. Int Immunol 2006; 18: 1265.
26. Taylor S, Alexander D, Cooper J, et al. Regulatory T cells are resistant to apoptosis via TCR but not P2X7. J Immunol 2007; 178: 3474.
27. Fritzsching B, Oberle N, Pauly E, et al. Naïve regulatory T cells: A novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood 2006; 108: 3371.
28. Kiener P, Davis P, Starling G, et al. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 1997; 185: 1511.
29. Oyaizu N, Adachi Y, Hashimoto F, et al. Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+T cells apoptosis. J Immunol 1997; 158: 2456.
30. Tedder T, Baras A, Xiu Y. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol 2006; 28: 351.
31. Oflazoglu E, Stone I, Gordon K, et al. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 2007; 110: 4370.
32. Oflazoglu E, Stone I, Brown L, et al. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer 2009; 100: 113.
33. Setiady Y, Coccia J, Park P. In vivo depletion of CD4+Foxp3+Treg cells by the PC61 ante-CD25 monoclonal antibody is mediated by FcyRIII+phagocytes. Eur J Immunol 2010; 40: 780.
34. Minard-Colin V, Xiu Y, Poe J, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcyRI, RCyRII and FcyRIV. Blood 2008; 112: 1205.
35. Hu Y, Turner M, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009; 128: 260.
36. Siders W, Shields J, Garron C, et al. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma 2010; 51: 1293.
37. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18: 1007.
38. Tao R, Hancock W. Regulating regulatory T cells to achieve transplant tolerance. Hepatobiliary Pancreat Dis Int 2007; 6: 348.
39. Ruzek M, Waire J, Hopkins D, et al. Characterization of in vitro antimurine thymocyte globulin induced regulatory T cells that inhibit graft-versus-host disease in vivo. Blood 2008; 111: 1726.
40. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994; 174: 83.
41. Van Rooijen N, Kors N, Ende M, et al. Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell Tissue Res 1990; 260: 215.